Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Looks For Advisory Panel's Blessing Of Development Pathway For Monoclonal Antibodies In Rabies PEP

Executive Summary

FDA's Division of Antiviral Products proposes a pathway for sponsors to develop monoclonal antibodies designed for rabies post-exposure prophylaxis as an alternative to anti-rabies virus immunoglobulin, but it wants input from an advisory committee before proceeding.

You may also be interested in...



How Do You Improve On A Cure? US FDA Panel Discusses Enrollment Conundrum

When the disease is deadly and the current standard of care is highly effective, would anyone join a clinical trial?

Rabies Monoclonal Antibody Development Plan Gets US FDA Panel Backing

A second-line indication for rabies post-exposure prophylaxis is the best a monoclonal antibody can initially expect, but postmarketing studies could get the product upgraded to first-line status, the Antimicrobial Drugs Advisory Committee suggests as it endorses the US FDA's proposed development plan in two separate 16-0 votes.

Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed

Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel